Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) received a Buy rating from analysts after strong Q3 2025 WAKIX performance, with revenue reaching $239 million, reflecting 29% growth.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY)
